Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer
The addition of hypoxia modifiers carbogen and nicotinamide (CON) to radiotherapy (RT) improved overall survival (OS) in bladder cancer patients in the BCON phase III clinical trial. We investigate whether expression of hsa-miR-210 in BCON patient samples reflects hypoxia and predicts benefit from h...
Hlavní autoři: | Irlam-Jones, J, Eustace, A, Denley, H, Choudhury, A, Harris, A, Hoskin, P, West, C |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Cancer Research UK
2016
|
Podobné jednotky
-
A gene signature for selecting benefit from hypoxia modification of radiotherapy for high risk bladder cancer patients
Autor: Yang, L, a další
Vydáno: (2017) -
A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
Autor: Eustace, A, a další
Vydáno: (2013) -
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial
Autor: Eustace, A, a další
Vydáno: (2013) -
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
Autor: Eustace, A, a další
Vydáno: (2013) -
Impact of Hypoxia-Induced miR-210 on Pancreatic Cancer
Autor: Mutian Lian, a další
Vydáno: (2023-12-01)